Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Amit Sanyal, MD: A Clinician’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Jul
16
Today In Oncology
ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite Maintenance Treatment vs 2-Years
Setmelanotide in Patients With Acquired Hypothalamic Obesity
Addition of Sacituzumab Tirumotecan to Pembrolizumab in PD-L1–Positive Advanced NSCLC
Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL
Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo